Having celebrated Thanksgiving with extended family members (with a nod to my British heritage we ate beef instead of turkey!), I have crammed a couple of weeks of news and observations into this edition. Although one wonders why we don’t keep things simple with one Budget a year, the recent Autumn Statement was the last […]
The Weeks That Were – 10 December 2014 Read More »
Certainly a busy time in the UK with a host of meetings taking place run by the likes of the Financial Times, ABPI (Association of the British Pharmaceutical Industry), Consilium Healthcare, Jefferies and Number 10. The big news was announcement of a government review of how new treatments and medical devices are developed and adopted
The Week that Was 24/11/14 Read More »
The realities of life within the European Union came to roost in three specific ways last week. First, with Germany leading international opposition to the scheme, the UK was forced to slightly water down its Patent Box initiative that had become a key attraction for overseas entities, both in terms of locating business in the
The Week That Was in UK Health & Life Sciences– 17/11/14 Read More »
A few challenging looks at the industry from the UK last week caught the eye. Be sure to check out our UK News postings. The Guardian reported an investigation that found Shire uses a chain of internal loans from Ireland and Luxembourg to lower its tax bill. An in-depth report illustrates this activity by pointing
The Week that Was in UK Health & Life Sciences 11/11/14 Read More »
While the world has fretted about the spectre of Ebola in our midst and the terrible impact on Africa, the issue of antibiotic resistance has remained very much at the forefront of a number of governments and global organisations like the WHO. A key issue has been how to make R&D surrounding antibiotics financially viable,
The week that was in UK Life Sciences – 3 November 2014 Read More »
As usual in the life science universe, there were a number of “reactions” to market forces over the last week. Shire is to remain independent as AbbVie bows to the growing aversion to inversion strategies, a somewhat short-lived financial strategy that spawned a slew of major potential acquisitions for tax purposes including Pfizer’s earlier pursuit
The Week That Was, 27 Oct 2014 Read More »
The weekly BELS blog will tend towards being a snapshot of newsworthy developments in the UK life sciences arena, some commentary and occasional humour. The premise behind BELS – British Expats in Life Sciences – is a fairly simple one. As a group of individuals our expat life scientists represent a tremendous value proposition in a
Welcome to BELS Blog Read More »
